Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 194.39M +90.4% |
| Revenue (ttm) | n/a |
| Net Income | -78.54M |
| EPS | -5.90 |
| Shares Out | 17.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,983 |
| Open | 10.88 |
| Previous Close | 10.87 |
| Day's Range | 10.79 - 11.28 |
| 52-Week Range | 6.25 - 20.56 |
| Beta | 2.68 |
| Analysts | Strong Buy |
| Price Target | 45.50 (+315.15%) |
| Earnings Date | May 22, 2026 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price target is $45.5, which is an increase of 315.15% from the latest price.
News
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announ...
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target The company’s lead asset CRB-701 is in development for second-line head and neck
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target
Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial
Corbus Pharmaceuticals (CRBP) announced the last patient has been enrolled and completed the first clinical visit in the company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of
Corbus reports FDA alignment for CRB-701, CMO Dominic Smethurst departure
Corbus Pharmaceuticals (CRBP) announced broad alignment with the FDA on the registration path for CRB-701, the company’s next-generation, highly stable Nectin-4 targeting ADC, in head and neck squamou...
Corbus Pharmaceuticals price target raised to $40 from $39 at Mizuho
Mizuho raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $40 from $39 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect
Corbus Pharmaceuticals files $300M mixed securities shelf
17:07 EDT Corbus Pharmaceuticals (CRBP) files $300M mixed securities shelf
Corbus Pharmaceuticals price target raised to $57 from $53 at Oppenheimer
Oppenheimer analyst Leland Gershell raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $57 from $53 and keeps an Outperform rating on the shares. On Monday, the company reported
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in onco...
Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Two lead clinical programs are advancing: CRB-701, a differentiated Nectin-4 ADC targeting underserved oncology indications, and CRB-913, a novel peripherally restricted CB1 inverse agonist for obesity, both with transformative data expected in 2024. CRB-701 shows strong safety and efficacy signals, while CRB-913 demonstrates rapid, significant weight loss with minimal neuropsychiatric risk.
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D....
Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
CRB-701 is advancing in head and neck and cervical cancer with key data and regulatory updates expected this year. CRB-913 shows strong early weight loss efficacy and safety, with no neuropsychiatric events, and a pivotal phase 1B study is planned. Cash reserves support operations into 2028.
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D....
RBC Capital says Corbus undervalued as ‘913 shows hints of weight loss
RBC Capital notes that Corbus Pharmaceuticals (CRBP) has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call
Corbus Pharmaceuticals Holdings Transcript: Study Update
CRB-913 showed strong safety and tolerability in a phase I SAD-MAD study, with minimal GI and neuropsychiatric adverse events and early, significant weight loss in participants with obesity. The drug’s peripherally restricted mechanism led to weight loss not driven by GI side effects, supporting its differentiated profile and potential for combination therapy.
Corbus Pharmaceuticals reports results from Phase 1a study of CRB-913 in obesity
Corbus Pharmaceuticals (CRBP) announced the completion of the single ascending dose, or SAD, and multiple ascending dose, or MAD, Phase 1a study of CRB-913 and the initiation of a Phase
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the s...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET
Corbus Pharmaceuticals Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key data from oncology and obesity programs are expected over the next 12-18 months, with a focus on differentiated safety and efficacy profiles. Strategic priorities include advancing pivotal studies in head and neck and cervical cancer, and progressing the CB1 obesity program, supported by a strong cash position.
Corbus Pharmaceuticals Holdings Transcript: Jefferies London Healthcare Conference 2025
The company highlighted strong efficacy and manageable safety for its Nectin-4 ADC in head and neck and cervical cancers, with key durability data expected mid-next year. Its obesity program will deliver phase 1B data in 2024, and a robust cash position supports multiple upcoming catalysts.
Corbus Pharmaceuticals price target lowered to $53 from $55 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $55 but keeps an Outperform rating on the shares. Following ESMO updates, the
Corbus Pharmaceuticals Holdings Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Three key assets are advancing: CRB-701 (Nectin-4 ADC) shows promising efficacy and safety in head and neck cancer, with a pivotal study planned for mid-next year. CRB-913 (obesity) and CRB-601 (solid tumors) are progressing, with major data readouts expected in 2024.
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be particip...
Corbus Pharmaceuticals Announces Pricing of Public Offering
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an u...
Corbus Pharmaceuticals Announces Proposed Public Offering
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to of...